title: [HIV seroprevalence among drug users in Togo].
abstract: BACKGROUND
  In the context of implementing a serological and behavioural surveillance system among drugs users, this study estimated the prevalence of HIV infection and related risk behaviours among drug users (DUs) in Togo.
  
  
  METHODS
  A cross-sectional study was conducted among DUs in Togo from November 2011 to January 2012. This study involved all DUs regardless of the type of drug and the mode of consumption, over the age of 18 years, who had lived in Togo for at least 3 months. Behavioural data were collected by face-to-face interviews and serum was obtained for HIV antibody testing. HIV prevalence was estimated together with its 95% confidence interval (CI). Univariate and then multivariate analyses were performed to study the factors associated with HIV prevalence.
  
  
  RESULTS
  A total of 387 DUs participated in the survey and 235 (60.7%) of them were enrolled in Lomé, the country's capital. The median age of DUs was 32 years with an interquartile range of [25-39 years] and 10 (2.6%) were women. The mode of drug consumption was: smoking or inhaling drugs in 92.8% of cases and 2.8% of DUs used drugs by injection. HIV testing was accepted in 98.4% of cases. The estimated HIV prevalence among drugs users was 5.5%, (95% CI, 3.2-7.8%).
  
  
  CONCLUSIONS
  This study, the first to be conducted among DUs in Togo, found an HIV prevalence of 5.5%, which is higher than the HIV prevalence in the general population (3.2% in 2010). Specific care of DUs is essential in order to reduce HIV prevalence in Togo.
authors.affiliation: Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
authors.forename: Didier K
authors.initials: DK
authors.lastname: Ekouevi
authors.affiliation: Programme PAC-CI, CHU de Treichville, Abidjan, Côte d'Ivoire.
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Coffie
authors.affiliation: Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
authors.forename: Mounerou
authors.initials: M
authors.lastname: Salou
authors.affiliation: Centre Africain de Recherche en Epidémiologie et Santé Publique, Lomé, Togo.
authors.forename: Benjamin G
authors.initials: BG
authors.lastname: Kariyiare
authors.affiliation: Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
authors.forename: Anoumou C
authors.initials: AC
authors.lastname: Dagnra
authors.affiliation: Programme PAC-CI, CHU de Treichville, Abidjan, Côte d'Ivoire.
authors.forename: Boris
authors.initials: B
authors.lastname: Tchounga
authors.affiliation: Département des Sciences Fondamentales et Santé Publique, Faculté Mixte de Médecine et de Pharmacie, Université de Lomé, Togo.
authors.forename: Mireille
authors.initials: M
authors.lastname: Prince-Davi
authors.affiliation: INSERM, Centre INSERM U897, Epidémiologie et Bio-statistique, Bordeaux, France.
authors.forename: Renaud
authors.initials: R
authors.lastname: Becquet
authors.affiliation: Programme National de Lutte contre le Sida, Ministère de la santé, Lomé, Togo.
authors.forename: Vincent P
authors.initials: VP
authors.lastname: Pitche
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D055030:Drug Users / Q000706:statistics & numerical data*; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000453:epidemiology*; D015528:HIV Seroprevalence; D006801:Humans; D008297:Male; D014037:Togo / Q000453:epidemiology